This website uses cookies to improve your experience. Learn more about cookies and how to manage them.

Dr Ann Hayes to chair joint steering committee for Society and ELRIG UK

Published: 05 Feb 2020 in Society news

The British Pharmacological Society and the European Laboratory Research & Innovation Group (ELRIG) UK today announced that Dr Ann Hayes has been selected to chair their joint steering committee. Dr Hayes will lead the committee to help ensure both organisations meet the objectives of the newly formed strategic alliance, which aims to bring new opportunities for education and networking in UK drug discovery and pharmacology.

Dr Ann Hayes is a well-respected member of the drug discovery and pharmacology community with expertise in central nervous system disorders. She has co-founded three drug discovery companies, and sits on the scientific advisory boards of several others. Dr Hayes has been a trustee of the British Pharmacological Society, and chaired the industry sub-committee from 2012 to 2015. Prior to this, she spent over 20 years in senior roles at Glaxo (then Glaxo Wellcome), most recently as the Director of Discovery Portfolio. She completed her PhD in Pharmacology at the School of Pharmacy in London.
 
Dr Del Trezise, ELRIG UK member of the joint steering committee, said:

Dr Hayes’ experience in pharmacology and drug discovery means she is ideally placed to bring together ideas from these complementary fields, helping ELRIG UK and the British Pharmacological Society reach a broad scientific audience.


Professor Clive Page, President Elect of the British Pharmacological Society and member of the joint steering committee, added:
 

We look forward to working closely with Dr Hayes to guide our strategic direction. This collaboration marks a new chapter of our history championing innovation in the life sciences and pharmacology.


  Dr Ann Hayes, Chair of the joint steering committee, commented:
 

I am honoured to be steering both organisations during our partnership. I will work hard with the committee to ensure we can meet our joint aims as organisations: to develop new openings for scientific exchange and collaboration, and to help drive the successful discovery and development of new medicines across the UK.